Longeveron (LGVN) Share-based Compensation (2020 - 2026)
Longeveron (LGVN) posted quarterly Share-based Compensation of $379000.0 for Q1 2026, up 11.47% year-over-year from $340000.0 in Q1 2025, and up 0.8% quarter-over-quarter from $376000.0 in Q4 2025.
Longeveron (LGVN) Share-based Compensation (2020 - 2026) Analysis & Trends
Longeveron's Share-based Compensation history runs 7 years deep, the most recent figure standing at $379000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 11.47% year-over-year to $379000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 27.69% YoY), while the FY2025 annual figure was $1.7 million, down 27.96% from the prior year.
- Share-based Compensation for Q1 2026 stood at $379000.0, up from $376000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.4 million in Q3 2024, with the low at $230000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $448000.0 (2025), against an average of $526647.1.
- Peak annual rise in Share-based Compensation reached 312.61% in 2022, while the deepest fall reached 89.49% in 2022.
- Longeveron's Share-based Compensation stood at $646000.0 in 2022, then plunged by 36.07% to $413000.0 in 2023, then declined by 5.57% to $390000.0 in 2024, then declined by 3.59% to $376000.0 in 2025, then grew by 0.8% to $379000.0 in 2026.
- Business Quant data shows LGVN's Share-based Compensation at $379000.0 in Q1 2026, $376000.0 in Q4 2025, and $448000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 373,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 373,000.00 |
| Jun 30, 2026 | 373,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Mar 31, 2026 | 379,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Sep 30, 2025 | 448,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Jun 30, 2025 | 513,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Mar 31, 2025 | 340,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Dec 31, 2024 | 390,000.00 |
| Sep 30, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 230,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Mar 31, 2024 | 295,000.00 |